OKYO Pharma Secures U.S. Patent for DED Therapy

OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.

OKYO Pharma Limited has announced the grant of a critical U.S. patent for OK-101, aimed at treating Dry Eye Disease (DED), marking a significant enhancement of the company’s intellectual property. The new patent supports OKYO Pharma’s strategy to develop innovative ocular therapies for DED and positions it to address a multi-billion-dollar market. OK-101, a lipid-conjugated chemerin peptide agonist, has shown promising results in a Phase 2 trial, indicating its potential efficacy in reducing inflammation and pain associated with DED.

For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.